Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + gemcitabine + bevacizumab
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of three drugs: oxaliplatin, gemcitabine, and bevacizumab. Oxaliplatin and gemcitabine are cytotoxic chemotherapy agents; oxaliplatin is a platinum-based DNA crosslinker that inhibits DNA replication and transcription, while gemcitabine is a nucleoside analog that inhibits DNA synthesis. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis in tumors. This combination has been studied in phase II clinical trials for advanced biliary tract cancers, hepatocellular carcinoma, pancreatic cancer, and recurrent Mullerian carcinoma. The regimen aims to combine direct cytotoxic effects with antiangiogenic therapy to improve tumor control[2][3][4][5][6].
- Brand names
- Avastin (for bevacizumab)
- Other names
- GEMOX-Bgemcitabine/oxaliplatin/bevacizumab
02
Targets
Beyond the preview
Go deeper on oxaliplatin + gemcitabine + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + gemcitabine + bevacizumab.